ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2025
Changes in ferroptosis-related molecular expression in macrophages of community-acquired pneumonia patients and their associated with the disease progression.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo investigate the expression of ferroptosis-related molecules in macrophages of community-acquired pneumonia (CAP) patients and explore their association with disease severity. This study provides novel insights into the role of ferroptosis in CAP pathogenesis by integrating transcriptome sequencing, RT-qPCR, Western blot, and flow cytometry analyses.
methodsFerroptosis-related molecules were analyzed in CD14⁺ monocytes and CD11b⁺ macrophages from CAP patients using transcriptome sequencing, RT-qPCR, Western blot, and flow cytometry. Clinical data from CAP patients (n = 46) and healthy controls (n = 63) were compared.
resultsCAP patients exhibited elevated levels of ferroptosis markers (PTGS2, Fe²⁺, and lipid peroxides) and downregulation of inhibitors (TP53 and GPX4). Transcriptome analysis showed activation of the ferroptosis pathway, with significant changes correlating with disease severity. Elevated neutrophil counts and decreased lymphocyte levels were also observed in CAP patients.
conclusionFerroptosis is intricately involved in CAP pathogenesis, with altered expression of key molecules contributing to disease progression. Our findings highlight the potential of targeting ferroptosis-related molecules (e.g., TP53, GPX4, and PTGS2) as a novel therapeutic strategy to mitigate inflammation and tissue damage in CAP. Future studies should validate these findings in larger cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.